SLS
A short seller with receipts
BMF Capital came out swinging at SELLAS Life Sciences, saying the biotech is dangerously overvalued heading into the Phase 3 REGAL trial readout. The firm’s big gripe: the market is treating a still-unresolved clinical event like a victory lap, which is a pretty classic biotech move when the data are still behind curtain number three.
Why the bear case is loud
The report argues the trial design leans on a tiny comparison group — just 10 selected patients — and says that’s not exactly the kind of sample size that inspires confidence. BMF also took aim at management history, repeated dilution, patent disclosures, and a past arbitration flap with 3D Medicines. In other words: not just “we don’t like the stock,” but “here’s the whole scrapbook.”
The market’s favorite kind of drama
SELLAS has been a retail darling, with a huge year-to-date run and plenty of Reddit optimism around its lead drug candidate, galinpepimut-S. That’s important because stocks like this can trade less like spreadsheets and more like sports teams — one trial result and suddenly everyone’s acting like they saw it coming all along.
What investors should watch
The real catalyst is the final REGAL analysis, which will come after the pre-specified 80th death event triggers database lock and review. Until then, expect the tape to stay jumpy, because when a short report lands before a binary clinical readout, traders tend to pick sides fast.
Big picture: SELLAS is now living the biotech cliché to the fullest — huge upside if the data hit, brutal downside if they don’t.